Abstract
Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).
| Original language | English |
|---|---|
| Pages (from-to) | 205-212 |
| Number of pages | 8 |
| Journal | Haematologica |
| Volume | 94 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2009 |
Fingerprint
Keywords
- Accelerated phase
- Chronic myeloid leukemia
- Imatinib
- Long-term results
ASJC Scopus subject areas
- Hematology
Cite this
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg : The GIMEMA CML Working Party experience after a 7-year follow-up. / Palandri, Francesca; Castagnetti, Fausto; Alimena, Giuliana; Testoni, Nicoletta; Breccia, Massimo; Luatti, Simona; Rege-Cambrin, Giovanna; Stagno, Fabio; Specchia, Giorgina; Martino, Bruno; Levato, Luciano; Merante, Serena; Liberati, Anna Maria; Pane, Fabrizio; Saglio, Giuseppe; Alberti, Daniele; Martinelli, Giovanni; Baccarani, Michele; Rosti, Gianantonio.
In: Haematologica, Vol. 94, No. 2, 02.2009, p. 205-212.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg
T2 - The GIMEMA CML Working Party experience after a 7-year follow-up
AU - Palandri, Francesca
AU - Castagnetti, Fausto
AU - Alimena, Giuliana
AU - Testoni, Nicoletta
AU - Breccia, Massimo
AU - Luatti, Simona
AU - Rege-Cambrin, Giovanna
AU - Stagno, Fabio
AU - Specchia, Giorgina
AU - Martino, Bruno
AU - Levato, Luciano
AU - Merante, Serena
AU - Liberati, Anna Maria
AU - Pane, Fabrizio
AU - Saglio, Giuseppe
AU - Alberti, Daniele
AU - Martinelli, Giovanni
AU - Baccarani, Michele
AU - Rosti, Gianantonio
PY - 2009/2
Y1 - 2009/2
N2 - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).
AB - Background: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. Design and Methods: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. Results: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. Conclusions: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia (clinicaltrials.gov identifier: NCT00514969).
KW - Accelerated phase
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Long-term results
UR - http://www.scopus.com/inward/record.url?scp=59549084574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59549084574&partnerID=8YFLogxK
U2 - 10.3324/haematol.13529
DO - 10.3324/haematol.13529
M3 - Article
C2 - 19144656
AN - SCOPUS:59549084574
VL - 94
SP - 205
EP - 212
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 2
ER -